FDA Approves Margenza to Treat HER2-Positive Breast Cancer

Published by W Butcher on

The FDA approved margetuximab-cmkb (Margenza, MacroGenics) in combination with chemotherapy for the treatment of adults with metastatic HER2-positive breast cancer who have received two or more anti-HER2 regimens, at least one of which was for metastatic disease.

Read More…

Categories: Uncategorized